Anti-human cd226 antibody and applications
By preparing and purifying anti-human CD226 antibodies and using flow cytometry to detect CD226 expression, the problem of inaccurate assessment of immune cell functional status in existing technologies has been solved, enabling accurate assessment of immune cell functional status and assisting in clinical diagnosis and treatment.
CN121342993BActive Publication Date: 2026-06-19TIANJIN KUANGBO TONGSHENG BIOTECHNOLOGY CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- TIANJIN KUANGBO TONGSHENG BIOTECHNOLOGY CO LTD
- Filing Date
- 2025-12-16
- Publication Date
- 2026-06-19
Smart Images
Figure CN121342993B_ABST
Abstract
This invention provides an anti-human CD226 antibody and its applications. The antibody includes a heavy chain variable region and a light chain variable region. The CDR1, CDR2, and CDR3 of the heavy chain variable region are the amino acid sequences shown in SEQ ID NO.1, SEQ ID NO.2, and SEQ ID NO.3, respectively. The CDR1, CDR2, and CDR3 of the light chain variable region are the amino acid sequences shown in SEQ ID NO.4, SEQ ID NO.5, and SEQ ID NO.6, respectively. The anti-human CD226 antibody of this invention is detected using flow cytometry. The expression status of CD226 on cells is determined based on changes in the intensity of the CD226 fluorescence signal, thus aiding in the assessment of the functional status of human immune cells.
Need to check novelty before this filing date? Find Prior Art